Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test

Cancer Discov. 2018 Apr;8(4):392-394. doi: 10.1158/2159-8290.CD-18-0124.

Abstract

<b/> Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of TP53 or BRCA2 or ATM detected in plasma have significantly worse outcomes on novel AR targeting. Cancer Discov; 8(4); 392-4. ©2018 AACR.See related article by Annala et al., p. 444.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Androstenes
  • Benzamides
  • Circulating Tumor DNA*
  • DNA
  • Genomics
  • Humans
  • Male
  • Nitriles
  • Phenylthiohydantoin / analogs & derivatives
  • Prostatic Neoplasms, Castration-Resistant / blood*

Substances

  • Androstenes
  • Benzamides
  • Circulating Tumor DNA
  • Nitriles
  • Phenylthiohydantoin
  • DNA
  • enzalutamide
  • abiraterone